<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">In the large study by Mao et al., 78 out of the 214 (36.4%) patients did show neurological manifestations. Among these, the most common were dizziness and headache, whereas the peripheral nervous system (PNS) manifestations mainly included alterations in smell and taste (up to 5.6 and 5.1% of patients, respectively) [
 <xref ref-type="bibr" rid="CR22">22</xref>]. Hitherto, the prevalence of COVID-19-related olfactory and taste disorders (OTDs) has been investigated through questionnaires and interviews [
 <xref ref-type="bibr" rid="CR26">26</xref>, 
 <xref ref-type="bibr" rid="CR27">27</xref>]. Results showed higher rates of OTDs in Europe compared with Asia and highlighted that olfactory disorders (both hyposmia and anosmia) are likely to appear even before other much-known symptoms of the COVID-19 [
 <xref ref-type="bibr" rid="CR26">26</xref>]. Given that the olfactory and sensory nerves are supposed to be the first route to CNS invasion, and that it may precede the viral spread to other related cerebral regions [
 <xref ref-type="bibr" rid="CR14">14</xref>], anosmia constitutes an interesting and early neurological manifestation of SARS-CoV-2 that may help for the timely suspicion and isolation of COVID-19 patients.
</p>
